AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITS AGREEMENTSeverance Benefits Agreement • August 6th, 2012 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
This AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITS AGREEMENT (the “Amendment”) is made and entered into, as of July 26, 2012 (the “Effective Date”), between ONYX PHARMACEUTICALS, INC., a Delaware corporation (“Company”), and KAYE FOSTER-CHEEK (“Executive”). As of the Effective Date, the Company and Executive hereby amend that certain AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITS AGREEMENT between the Company and Executive dated May 18, 2011 (the “Agreement”), a copy of which is attached hereto as Exhibit A, as follows:
